XML 83 R21.htm IDEA: XBRL DOCUMENT
v3.20.1

Stock Transactions And Stock-Based Compensation | 3 Months Ended
--- | ---
Apr. 03, 2020
Share-based Payment Arrangement [Abstract] |
Stock Transactions And Stock-Based Compensation | STOCK TRANSACTIONS AND STOCK-BASED COMPENSATION Neither the Company nor any “affiliated purchaser” repurchased any shares of Company common stock during the three-month period ended April 3, 2020. On July 16, 2013, the Company’s Board of Directors approved a repurchase program (the “Repurchase Program”) authorizing the repurchase of up to 20 million shares of the Company’s common stock from time to time on the open market or in privately negotiated transactions. As of April 3, 2020, 20 million shares remained available for repurchase pursuant to the Repurchase Program. The following table summarizes the Company’s share activity (shares in millions):
| Three-Month Period Ended
| April 3, 2020 |  | March 29, 2019
Preferred stock - shares issued: |  |  |
Balance, beginning of period | 1.7 |  |  | — |
Issuance of MCPS | — |  |  | 1.7 |
Balance, end of period | 1.7 |  |  | 1.7 |
Common stock - shares issued: |  |  |
Balance, beginning of period | 835.5 |  |  | 817.9 |
Common stock-based compensation awards | 1.8 |  |  | 2.0 |
Common stock issued in connection with LYONs’ conversions | — |  |  | 0.5 |
Issuance of common stock | — |  |  | 12.1 |
Balance, end of period | 837.3 |  |  | 832.5 |
On March 1, 2019, the Company completed the underwritten public offering of 12.1 million shares of Danaher common stock at a price to the public of $123.00 per share (the “Common Stock Offering”), resulting in net proceeds of approximately $1.4 billion, after deducting expenses and the underwriters’ discount of $45 million. Simultaneously, the Company completed the underwritten public offering of 1.65 million shares of its 4.75% MCPS, Series A, without par value and with a liquidation preference of $1,000 per share (the “MCPS Offering”), resulting in net proceeds of approximately $1.6 billion, after deducting expenses and the underwriters’ discount of $50 million. The Company used the net proceeds from the Common Stock Offering and the MCPS Offering to fund a portion of the cash consideration payable for, and certain costs associated with, the Cytiva Acquisition. Prior to the completion of the Cytiva Acquisition, the Company invested the net proceeds in short-term bank deposits and/or interest-bearing, investment-grade securities. Taking into account the anti-dilution adjustments as a result of the dividends paid to the Company’s common shareholders on or prior to April 3, 2020, each share of MCPS will mandatorily convert on the mandatory conversion date, which is expected to be April 15, 2022, into between 6.6542 and 8.1513 shares of the Company’s common stock, subject to further anti-dilution adjustments. The number of shares of the Company’s common stock issuable upon conversion will be determined based on the average volume-weighted average price per share of the Company’s common stock over the 20 consecutive trading day period beginning on, and including, the 21st scheduled trading day immediately before April 15, 2022. Subject to certain exceptions, at any time prior to April 15, 2022, holders may elect to convert each share of the MCPS into 6.6542 shares of common stock, subject to further anti-dilution adjustments. In the event of a fundamental change, the MCPS will convert at the fundamental change rates specified in the certificate of designations, and the holders of MCPS would be entitled to a fundamental change make-whole dividend. Holders of MCPS will be entitled to receive, when and if declared by the Company’s Board of Directors, cumulative dividends at the annual rate of 4.75% of the liquidation preference of $1,000 per share (equivalent to $47.50 annually per share), payable in cash or, subject to certain limitations, by delivery of shares of the Company’s common stock or any combination of cash and shares of the Company’s common stock, at the Company’s election. If declared, dividends on the MCPS are payable quarterly on January 15, April 15, July 15 and October 15 of each year (to, and including, April 15, 2022), to the holders of record of the MCPS as they appear on the Company’s stock register at the close of business on the immediately preceding December 31, March 31, June 30 and September 30, respectively. For a full description of the Company’s stock-based compensation programs, refer to Note 19 of the Company’s financial statements as of and for the year ended December 31, 2019 included in the Company’s 2019 Annual Report. As of April 3, 2020, approximately 55 million shares of the Company’s common stock were reserved for issuance under the 2007 Omnibus Incentive Plan. The following summarizes the components of the Company’s stock-based compensation expense ($ in millions):
| Three-Month Period Ended
| April 3, 2020 |  | March 29, 2019
Restricted stock units (“RSUs”)/performance stock units (“PSUs”): |  |  |
Pretax compensation expense | $ | 27.6 |  |  | $ | 21.7 |
Income tax benefit | (5.7 | ) |  | (4.5 | )
RSU/PSU expense, net of income taxes | 21.9 |  |  | 17.2 |
Stock options: |  |  |
Pretax compensation expense | 17.6 |  |  | 13.4 |
Income tax benefit | (3.6 | ) |  | (2.8 | )
Stock option expense, net of income taxes | 14.0 |  |  | 10.6 |
Total stock-based compensation: |  |  |
Pretax compensation expense | 45.2 |  |  | 35.1 |
Income tax benefit | (9.3 | ) |  | (7.3 | )
Total stock-based compensation expense, net of income taxes | $ | 35.9 |  |  | $ | 27.8 |
Stock-based compensation has been recognized as a component of selling, general and administrative expenses in the accompanying Consolidated Condensed Statements of Earnings. As of April 3, 2020, $231 million of total unrecognized compensation cost related to RSUs/PSUs is expected to be recognized over a weighted average period of approximately three years. As of April 3, 2020, $204 million of total unrecognized compensation cost related to stock options is expected to be recognized over a weighted average period of approximately three years. Future compensation amounts will be adjusted for any changes in estimated forfeitures.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration